[1]李越,梁键莹,程茹虹,等.庆大霉素软膏治疗无义突变引起的营养不良性大疱性表皮松解症的临床疗效观察[J].中国皮肤性病学杂志,2020,(06):650-654.[doi:10.13735/j.cjdv.1001-7089.201909131]
 LI Yue,LIANG Jianying,CHENG Ruhong,et al.Clinical Efficacy of Gentamicin Ointment in the Treatment of Dystrophic Bullous Epidermolysis Caused by Nonsense Mutation[J].The Chinese Journal of Dermatovenereology,2020,(06):650-654.[doi:10.13735/j.cjdv.1001-7089.201909131]
点击复制

庆大霉素软膏治疗无义突变引起的营养不良性大疱性表皮松解症的临床疗效观察
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2020年06期
页码:
650-654
栏目:
临床经验
出版日期:
2020-06-01

文章信息/Info

Title:
Clinical Efficacy of Gentamicin Ointment in the Treatment of Dystrophic Bullous Epidermolysis Caused by Nonsense Mutation
文章编号:
1001-7089(2020)06-0650-05
作者:
李越12梁键莹12程茹虹12张佳12姚志荣12李明12
1.上海交通大学医学院附属新华医院,上海 200092; 2.上海交通大学医学院皮肤病研究所,上海 200092
Author(s):
LI Yue12LIANG Jianying12CHENG Ruhong12ZHANG Jia12YAO Zhirong12LI Ming12
(1.Department of Dermatology,Xinhua Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200092,China; 2.Institute of Dermatology,Shanghai Jiaotong University School of Medicine,Shanghai 200092,China)
关键词:
营养不良性大疱性表皮松解症 通读治疗 庆大霉素 无义突变
Keywords:
RDEB Readthrough Nonsense mutation Gentamicin
分类号:
R 758.5
DOI:
10.13735/j.cjdv.1001-7089.201909131
文献标志码:
B
摘要:
目的 观察评价庆大霉素软膏外用治疗无义突变所致常染色体隐性营养不良性大疱性表皮松解症(RDEB)的有效性及安全性。方法 2018年3月-2019年2月,笔者采用随机、双盲、安慰剂对照的研究方法,安慰剂选用与庆大霉素软膏相同的赋形剂成分,招募基因检测确诊为无义突变导致的RDEB患者,通过安全性评估后,每例患者每日涂抹1次庆大霉素乳膏于患处(共30 d),分别进行疗效和安全性观察。治疗期间使用皮肤生活质量问卷(DLPI)和伯明翰大疱性表皮松解症严重程度评分(BEBS)对患者进行评估。结果 共纳入4名患者,经基因检测均携带有杂合无义突变,年龄2~26岁。DLPI评分治疗前为(24.50±1.73)分,治疗后为(17.75±1.25)分。BEBS治疗前为(28.75±9.98)分,治疗后为(22.00±6.36)分。临床可见用药侧效果明显优于安慰剂侧,治疗期间与治疗后均无相关不良反应发生。免疫荧光显示患者Ⅶ型胶原纤维有部分表达。结论 使用庆大霉素软膏治疗由无义突变引起的RDEB,可以提高患者皮损的愈合速度,减少起疱频率,显著改善患者生活质量,减轻日常护理的压力。
Abstract:
Objective To evaluate the efficacy and safety of gentamicin ointment in the treatment of recessive dystrophic epidermolysis bullosa(RDEB)caused by nonsense mutations.Methods From March 2018 to February 2019,a randomized,double-blind,placebo-controlled study was conducted in Xinhua Hospital.The placebo was selected from the same excipients as gentamicin ointment.Patients with RDEB was enrolled after their genetic test was diagnosed as nonsense mutations,and they were given a daily gentamicin cream on affected area(Day 1-Day 30).The efficacy and safety were observed separately.During the treatment,the skin quality of life questionnaire(DLPI)and the Birmingham epidermolysis bullosa severity score(BEBS)were used to evaluate the patients.Results A total of 4 patients were enrolled.All of them were heterozygous nonsense mutations,and the age was between 2~26 years.The DLPI score was(24.50±1.73)points before treatment and(17.75±1.25)points after treatment.The BEBS was(28.75±9.98)points before treatment and(22.00±6.36)point after treatment.The therapeutic effect of the research group was better than that of the placebo group.There was no significant side effects observed during the treatment period.The immunofluorescence showed that the type Ⅶ collagen was partially expressed in the basement membrane zone(BMZ)of patients.Conclusion The use of gentamicin ointment to treat RDEB caused by nonsense mutations can improve the healing process of skin lesions,and reduce the frequency of blistering.And it can improve the quality of life of patients significantly,while reducing the burden of nursing.

参考文献/References:

[1] Fine JD,Bruckner-Tuderman L,Eady RA,et al.Inherited epidermolysis bullosa:updated recommendations on diagnosis and classification[J].J Am Acad Dermatol,2014,70(6):1103-1126.
[2] Osborn MJ,Starker CG,Mcelroy AN,et al.TALEN based gene correction for epidermolysis bullosa [J].Mol Ther,2013,21(6):1151-1159.
[3] Tockner B,Kocher T,Hainzl S,et al.Construction and validation of an RNA trans-splicing molecule suitable to repair a large number of COL7A1mutations[J].Gene Ther,2016,23(11):775-784.
[4] South AP,Uitto J.Type Ⅶ collagen replacement therapy in recessive dystrophic epidermolysis bullosa-how much,how often?[J].J Invest Dermatol,2016,136(6):1079-1081.
[5] Islam MA,Alam F,Kamal MA,et al.Therapeutic suppression of nonsense mutation:an emerging target in multiple diseases and thrombotic disorders[J].Curr Pharm Des,2017,23(11):1598-1609.
[6] Woodley DT,Cogan J,Hou Y,et al.Gentamicin induces functional type Ⅶ collagen in recessive dystrophic epidermolysis bullosa patients[J].J Clin Invest,2017,127(8):3028-3038.
[7] Beznoskova P,Wagner S,Jansen ME,et al.Translation initiation factor eIF3 promotes programmed stop codon readthrough[J].Nucleic Acids Res,2015,43(10):5099-5111.
[8] Miller JN,Kovacs AD,Pearce DA.The novel Cln1R151X mouse model of infantile neuronal ceroid lipofuscinosis(INCL)for testing nonsense suppression therapy[J].Hum Mol Genet,2015,24(1):185-196.
[9] Cogan J,Weinstein J,Wang X,et al.Aminoglycosides restore full-iength type vII collagen by overcoming premature termination codons:therapeutic implications for dystrophic epidermolysis bullosa[J].Mol Ther,2014,22(10):1741-1752.
[10] Ohguchi Y,Nomura T,Suzuki S,et al.Gentamicin-induced readthrough and nonsense-mediated mRNA decay of SERPINB7 nonsense mutant transcripts[J].J Invest Dermatol,2018,138(4):836-843.
[11] Fabian S,Sven T.Functional translational readthrough:a systems biology perspective[J].PLoS Genet,2016,12(8):e1006196.

备注/Memo

备注/Memo:
[基金项目] 上海市教委高峰高原计划—“研究型医师”项目基金(20161417); 上海交通大学医工交叉项目基金(YG2017MS73)
[通信作者] 李明,E-mail:liming01@xinhuamed.com.cn
[Corresponding author]LI Ming,E-mail:liming01@xinhuamed.com.cn
更新日期/Last Update: 2020-06-05